D-0390-2024 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0390-2024 was initiated by Eugia US LLC on Feb 20, 2024 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification for organic impurities The recall status is ongoing. Affected quantity: 335,940 vials.

Recall details

Product Type
Drugs
Report Date
Mar 27, 2024
Initiation Date
Feb 20, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
335,940 vials

Product description

Nicardipine Hydrochloride Injection (2.5mg/mL), US, 25mg per 10mL, 10mL Vial, Rx only, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520 NDC 55150-183-10

Reason for recall

Failed Impurities/Degradation Specifications: Out of specification for organic impurities

Distribution pattern

Nationwide within the United States

Code information

Lot #: 3NC23002, Exp. Date 7/24; 3NC22013, 3NC22014, 3NC22015, 3NC22016, 3NC22017, 3NC22018, Exp. Date 2/24; 3NC22020, Exp. Date 3/24

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0390-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0390-2024. Report a data issue: hello@regdatalab.com.